Last updated: August 1, 2026
Fungizone is the legacy brand for amphotericin B deoxycholate, an intravenous polyene antifungal. Its active ingredient remains clinically important for severe systemic fungal infections, cryptococcosis, mucormycosis and selected parasitic diseases, but the original deoxycholate formulation has largely lost share to liposomal amphotericin B and other less nephrotoxic alternatives. Fungizone has no meaningful remaining branded patent moat, no material regulatory exclusivity and limited prospects for prescription-market growth.
What is Fungizone and how is it used?
Fungizone contains amphotericin B deoxycholate for intravenous administration. The conventional formulation binds ergosterol in fungal cell membranes, creating membrane pores and causing fungal-cell death.
The FDA-approved label covers serious, potentially life-threatening systemic mycotic infections, including:
- Cryptococcosis
- Coccidioidomycosis
- Histoplasmosis
- Blastomycosis
- Sporotrichosis
- Aspergillosis
- North American leishmaniasis in selected treatment settings
The formulation is generally administered by intravenous infusion. A typical vial contains 50 mg of amphotericin B, although hospital dosing is weight-based and depends on the indication, renal function and treatment response.[1]
How does Fungizone differ from liposomal amphotericin B?
| Attribute |
Fungizone |
Liposomal amphotericin B |
| Active ingredient |
Amphotericin B deoxycholate |
Amphotericin B in liposomes |
| Common brand |
Fungizone |
AmBisome |
| Administration |
Intravenous infusion |
Intravenous infusion |
| Kidney toxicity |
High relative risk |
Lower relative risk |
| Infusion reactions |
Frequent |
Lower frequency in many patients |
| Manufacturing complexity |
Conventional formulation |
Complex liposomal delivery system |
| Typical use |
Cost-sensitive or resource-limited settings |
Preferred for many severe invasive infections |
| Patent position |
Legacy, expired technology |
Historical formulation and manufacturing patent estate, largely mature |
| Generic competition |
Broad |
More limited than deoxycholate products |
Liposomal amphotericin B has displaced conventional amphotericin B in many high-income-country treatment protocols because of improved tolerability. The 2017 World Health Organization cryptococcal disease guidance and subsequent global treatment guidance support liposomal amphotericin B where available, particularly for severe cryptococcal disease.[2]
What is the current FDA regulatory status of Fungizone?
Fungizone is an established intravenous amphotericin B product rather than a recently approved medicine. Its regulatory value is tied to the amphotericin B active ingredient and manufacturing authorization, not to current market exclusivity.
The FDA-approved product labeling identifies major toxicities that include:
- Nephrotoxicity
- Hypokalemia
- Hypomagnesemia
- Anemia
- Fever and chills
- Thrombophlebitis
- Infusion-related reactions
Renal monitoring, electrolyte monitoring and dose adjustment are central to treatment. Conventional amphotericin B has a narrower practical safety margin than liposomal formulations.[1]
The FDA has also approved multiple generic amphotericin B for injection products. The availability of abbreviated new drug application products means that Fungizone competes in a multisource hospital market rather than a protected branded market.[3]
What is the Orange Book status of Fungizone?
Fungizone does not have a commercially meaningful Orange Book patent position. The original amphotericin B composition and conventional deoxycholate formulation were developed many decades ago, and any foundational patents have expired.
Current commercial protection, where it exists, relates to:
- Product-specific manufacturing controls
- Supplier contracts
- Drug-master-file information
- Sterile injectable production capacity
- Quality systems
- Regulatory approvals
- Hospital purchasing agreements
Those factors can affect competition without creating patent exclusivity.
What clinical trials are evaluating Fungizone?
There is no major late-stage development program centered on Fungizone as a branded product. Contemporary clinical research generally evaluates amphotericin B as an active ingredient, or compares conventional amphotericin B with liposomal amphotericin B and oral antifungal regimens.
ClinicalTrials.gov records have historically included amphotericin B studies in:
- Cryptococcal meningitis
- Invasive candidiasis
- Mucormycosis
- Visceral leishmaniasis
- Cutaneous leishmaniasis
- Neonatal and pediatric fungal infections
- Empirical treatment of febrile neutropenia
- HIV-associated opportunistic infections
- Combination regimens involving flucytosine, azoles or newer antifungals
Most recent high-impact research has focused on reducing toxicity, improving treatment access or optimizing combinations. The branded Fungizone name is generally absent from modern development programs because investigators use the generic name, a liposomal formulation or a study-specific formulation.
What is the current clinical-trial direction for amphotericin B?
The strongest clinical development trend is toward safer delivery and shorter treatment courses.
In cryptococcal meningitis, a single high dose of liposomal amphotericin B combined with flucytosine and fluconazole was shown to improve practical treatment delivery in resource-limited settings compared with longer conventional amphotericin B regimens.[4] This development supports amphotericin B use but does not strengthen the commercial outlook for conventional Fungizone.
In mucormycosis, amphotericin B remains a foundational treatment, particularly in severe disease. Liposomal amphotericin B is generally favored because patients often have renal compromise, diabetes, malignancy or other conditions that increase toxicity risk.[5]
In visceral leishmaniasis, liposomal amphotericin B has strong clinical and public-health relevance because of its efficacy and shorter treatment courses. Conventional amphotericin B remains a lower-cost option in some settings but is less attractive where liposomal product is accessible.[6]
When does Fungizone lose exclusivity?
Fungizone has already lost primary market exclusivity. The product is a legacy off-patent injectable antifungal.
| Exclusivity category |
Fungizone position |
| Active-ingredient patent |
Expired |
| Original formulation patent |
Expired |
| New chemical entity exclusivity |
Expired decades ago |
| Pediatric exclusivity |
No current commercial relevance |
| Orphan exclusivity |
No current Fungizone-specific protection |
| Data exclusivity |
Expired |
| Orange Book patent term |
No material live estate |
| Generic substitution risk |
High |
The principal barriers are technical and operational rather than legal. Sterile injectable manufacturing requires validated aseptic processes, reliable amphotericin B supply and compliance with current good manufacturing practice. These barriers can create temporary shortages or supplier concentration, but they do not prevent generic entry.
How many patents cover Fungizone?
No meaningful active patent estate covers the conventional Fungizone product as a branded commercial platform.
The historical patent landscape includes broad amphotericin B chemistry, formulations and production disclosures. Those rights are now expired or have limited practical relevance. Patent activity has shifted toward:
- Liposomal amphotericin B
- Nanoformulations
- Oral amphotericin B delivery
- Targeted antifungal delivery
- Combination therapies
- Reduced-toxicity formulations
- Alternative polyene derivatives
These newer patents generally do not protect the conventional Fungizone product.
What formulations are protected instead of Fungizone?
The more defensible intellectual-property positions have involved delivery technologies that modify amphotericin B exposure or tolerability. Examples include liposomes, nanoparticles, emulsions, oral delivery systems and tissue-targeted formulations.
A company seeking to commercialize a new amphotericin B product would likely pursue protection around:
- Particle size and composition
- Encapsulation efficiency
- Release profile
- Stability and storage conditions
- Administration route
- Dosing schedule
- Combination treatment
- Manufacturing process
These claims are distinct from the expired conventional deoxycholate formulation.
What is the Fungizone market size and commercial outlook?
No reliable public financial reporting isolates Fungizone revenue from broader amphotericin B or hospital antifungal sales. The brand is not a separately disclosed revenue segment for major pharmaceutical companies.
The commercial market has three layers:
| Market segment |
Fungizone outlook |
| High-income hospital systems |
Declining or stable at a low base |
| Low- and middle-income markets |
Continued demand based on price and availability |
| Severe invasive fungal infections |
Active demand, but mainly shifting toward liposomal product |
| Leishmaniasis programs |
Demand depends on public procurement and regional guidelines |
| Cryptococcal disease programs |
Conventional use persists where liposomal supply is limited |
| Private retail market |
Minimal because treatment is hospital-based |
What factors will drive Fungizone demand?
Demand will remain tied to clinical necessity rather than brand promotion. The main drivers are:
- Hospital incidence of invasive fungal infections
- Growth in immunocompromised populations
- Cancer chemotherapy and transplant activity
- HIV-associated cryptococcal disease
- Mucormycosis incidence
- Public-health programs for leishmaniasis
- Liposomal amphotericin B availability
- Procurement budgets
- Generic manufacturing capacity
- Regional shortages of newer antifungals
The strongest negative factor is substitution by liposomal amphotericin B. The strongest positive factors are low acquisition cost, established efficacy and use in countries where liposomal product is unavailable or unaffordable.
What is the Fungizone market projection through 2030?
The most defensible projection is a mature, low-growth or declining branded market with continuing generic demand.
| Scenario through 2030 |
Expected market direction |
Main assumptions |
| Base case |
Low-single-digit annual volume decline in conventional formulation |
Continued substitution by liposomal amphotericin B |
| Downside case |
Faster decline |
Wider liposomal access and lower conventional-product procurement |
| Resilience case |
Flat to low-single-digit growth in selected regions |
Persistent shortages, price pressure and public-health demand |
Revenue may decline faster than unit volume if procurement prices continue to fall. Conventional amphotericin B can maintain or increase unit demand in low-resource settings while losing value share to higher-priced liposomal products.
The commercial opportunity is therefore more attractive for manufacturers with low-cost sterile production and reliable supply than for a company attempting to build a premium branded Fungizone franchise.
Which companies compete with Fungizone?
Competition comes from both conventional amphotericin B suppliers and alternative antifungal products.
Conventional amphotericin B competitors
Generic manufacturers and hospital suppliers compete primarily on:
- Price
- Supply reliability
- Regulatory status
- Vial availability
- Hospital contracts
- Regional distribution
The market is fragmented across jurisdictions. Product names and suppliers differ by country, and some markets list the product only as amphotericin B for injection rather than Fungizone.
Therapeutic competitors
Fungizone competes clinically with:
- Liposomal amphotericin B, including AmBisome
- Amphotericin B lipid complex
- Isavuconazole
- Posaconazole
- Voriconazole
- Fluconazole
- Flucytosine
- Echinocandins for susceptible Candida infections
The competitive threat differs by indication. For cryptococcal meningitis and mucormycosis, amphotericin B remains important. For many Candida infections, echinocandins are preferred. For selected mold infections, triazoles can reduce reliance on amphotericin B.
What patent litigation affects Fungizone?
No major current patent litigation is associated with the conventional Fungizone brand. The product is too mature to support a conventional Paragraph IV launch dispute of the type seen with recently approved small-molecule medicines.
Are there Paragraph IV challenges to Fungizone?
Paragraph IV litigation is not a material current risk factor for Fungizone. Generic amphotericin B products entered a market with expired foundational rights and no commercially significant patent barrier.
Any dispute involving a current amphotericin B product would more likely concern:
- Manufacturing patents
- Liposomal composition claims
- Process patents
- Regulatory compliance
- Product quality
- Supply contracts
- Trade secrets
Those issues are separate from the conventional Fungizone molecule and deoxycholate formulation.
What generic entry risks exist for Fungizone?
Generic entry risk is already realized rather than prospective. The main commercial risks are:
- Price erosion
- Hospital formulary substitution
- Loss of brand recognition
- Reduced purchasing volume
- Supply interruptions
- Competition from liposomal amphotericin B
- Regulatory action involving sterile injectable quality
- Procurement concentration among a small number of suppliers
Manufacturing capacity is the most important practical barrier. Amphotericin B injection is a sterile product, and shortages can occur even in an off-patent market if manufacturers exit, face inspection findings or experience raw-material constraints.
How strong is the Fungizone patent estate?
The Fungizone patent estate is weak for commercial purposes.
| Patent-estate criterion |
Assessment |
| Foundational composition claims |
Expired |
| Conventional formulation claims |
Expired |
| Product-specific exclusivity |
None of material commercial duration |
| Generic blocking power |
None |
| Litigation leverage |
Very low |
| Manufacturing know-how value |
Moderate |
| Supply-chain value |
Moderate to high in shortage markets |
| Product differentiation |
Low |
The asset has clinical utility but little residual patent value. Its strategic value is based on manufacturing reliability, regulatory history and access to hospital procurement channels.
Key Takeaways
- Fungizone is amphotericin B deoxycholate, an established intravenous antifungal.
- The product has no meaningful current patent or regulatory exclusivity.
- Conventional amphotericin B remains clinically relevant for severe fungal disease and leishmaniasis.
- Liposomal amphotericin B has taken share because of lower kidney toxicity and improved tolerability.
- Modern clinical trials generally evaluate amphotericin B by active ingredient or formulation, not the Fungizone brand.
- No major current Paragraph IV or patent-litigation threat affects conventional Fungizone.
- The market outlook is mature, with likely low-single-digit volume decline through 2030 in developed markets.
- Continued demand is likely in low-resource settings where price and availability outweigh toxicity advantages.
- Manufacturing capacity, sterile production and public procurement are more important than patents.
- The commercial opportunity is strongest for reliable generic suppliers, not for a premium branded relaunch.
FAQs
Is Fungizone still used for cryptococcal meningitis?
Yes. Conventional amphotericin B remains an option where liposomal amphotericin B is unavailable, although current treatment guidance often favors liposomal amphotericin B because of lower toxicity.[2][4]
Is Fungizone the same as AmBisome?
No. Both contain amphotericin B, but Fungizone is the conventional deoxycholate formulation and AmBisome is a liposomal formulation with different pharmacokinetics, tolerability and manufacturing characteristics.
Can Fungizone treat mucormycosis?
Amphotericin B is a first-line treatment class for serious mucormycosis. Liposomal amphotericin B is generally preferred over conventional deoxycholate amphotericin B when available.[5]
Does Fungizone have biosimilar competition?
No. Fungizone is a small-molecule antifungal, not a biologic. It faces generic competition rather than biosimilar competition.
Is Fungizone commercially attractive for a pharmaceutical company?
Only in selected circumstances. The strongest opportunities involve low-cost sterile manufacturing, reliable supply, government procurement and markets with limited access to liposomal amphotericin B. Patent-based pricing power is absent.
References
-
U.S. Food and Drug Administration. (n.d.). Fungizone amphotericin B for injection prescribing information. FDA/DailyMed.
-
World Health Organization. (2022). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. World Health Organization.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
World Health Organization. (2022). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Evidence and treatment recommendations for liposomal amphotericin B-based induction therapy.
-
Cornely, O. A., Alas true? Need correct citation. Let's ensure reference. Cornely et al 2019 global guideline.
-
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., et al. (2019). Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet Infectious Diseases, 19(12), e405-e421.
-
World Health Organization. (2010). Control of the leishmaniases. WHO Technical Report Series 949.
